Kodiak Sciences Inc. (KOD)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kodiak Sciences Inc. ("Kodiak" or "the Company") (NASDAQ: KOD). The investigation concerns whether Kodiak and certain of its officers and/or directors have violated federal securities laws.

 

On May 10, 2021, Kodiak issued a press release “report[ing] business highlights and financial results for the first quarter ended March 31, 2021.”  The press release included an update regarding the path to licensure for the Company’s product KSI301, a proposed anti-vascular endothelial growth factor medicine.  Specifically, Kodiak disclosed that “through our continued engagement with the retina community, we have learned that physicians and retina practices would like to see our labeling for KSI-301 include the option for more frequent dosing.”  Accordingly, the Company announced the launch of the DAYLIGHT study which will evaluate monthly dosing of KSI-301 in patients with wet AMD.”  Kodiak stated that it “expect[s] recruitment in DAYLIGHT will begin in the summer of 2021, and we plan to include data from this fifth pivotal study of KSI-301 in our initial BLA submission.”  On this news, Kodiak’s stock price fell $13.21 per share, or 13%, to close at $88.41 per share on May 10, 2021.

 

If you are aware of any facts relating to this investigation, or purchased Kodiak shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.